HNSCC
-
As the 10th anniversary of approval approaches，Keytruda adds ‘potential’ performance to Merck
DrugTimes will follow up on this subject. Please stay tuned
-
Cell子刊：王存玉院士团队发现靶向BMI1，可抑制癌症干细胞，显著提高癌症联合治疗效果
本文转载自药研网，作者灵犀 点击阅读原文 头颈部鳞状细胞癌（HNSCC）是一种常见的癌症，占据了超过90%的头颈部肿瘤，HNSCC五年生存率低，且预后较差。近十年来，HNSCC发布…
